NPR had an interesting segment this morning on the issue of Medicare's payment for experimental drugs under the new prescription drug plan. The piece reported that these drugs can be very expensive. Of course, in almost no cases are these drugs actually expensive to produce. They are expensive because of government granted patent monopolies.
It would be useful if NPR would occasionally talk about the costs of this patent protection. Economists typically get very upset over tariffs or quotas that raise the price of imported goods by 10-20 percent. In the case of the drugs mentioned, patent protection is raising the prices by several thousand percent. It would have been useful to note this fact.
If you enjoyed this article, please consider making a tax-deductible donation today. For over 30 years, The American Prospect has delivered independent reporting that exposes corporate power, investigates political corruption, and analyzes threats to our democracy. Unlike many media outlets, we’re not owned by billionaires or corporations—we’re powered by readers like you.
Today’s independent journalism faces unprecedented challenges. Your support makes our reporting possible and keeps our work free and accessible to all. Whether it’s $5 or $50, every contribution helps sustain our nonprofit newsroom.
Join our community of supporters and make a donation today to help keep independent journalism thriving.
Copyright 2025 | The American Prospect, Inc. | All Rights Reserved